BridgeMD
The effect of corticosteroids on early recovery after major surgery in eldery patients: CORTERAS study
EU CTIS ID: 2024-517602-28-00
What this study is testing
The main objective of this prospective trial is to evaluate the effect of moderate dose corticosteroids on early post-operative outcome, focusing on muscle weakness, in elderly patients (≥60 years) undergoing complex major surgery.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged 60 years or older
- Scheduled for a complex major surgical procedure
You likely can't join if
- Lack of informed consent or inability to give informed consent
- Severe PONV, needing corticosteroids as PONV prophylaxis
- Urgent, not elective surgery
- Hypersensitivity or known allergic reaction to methylprednisolone
- Preoperative use of steroids: including, but not limited to, the use of corticosteroids < 4 weeks before surgery of at least 4 mg methylprednisolone equivalents; excluding inhalational steroids
- Preexisting muscle disease: including, but not limited to, Steinert's disease, amyotrophic lateral sclerosis (ALS), Duchenne dystrophy, amputation of dominant arm or hand
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.